Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy.

Autor: Chand D; Agenus (United States), Lexington, MA, United States., Savitsky DA; Agenus, Lexington, MA, United States., Krishnan S; Agenus (United States), Lexington, MA, United States., Mednick G; Agenus (United States), Lexington, MA, United States., Delepine C; Agenus (United States), Lexington, MA, United States., Garcia-Broncano P; Agenus (United States), Lexington, MA, United States., Soh KT; Agenus (United States), Lexington, MA, United States., Wu W; Agenus (United States), Lexington, MA, United States., Wilkens MK; Agenus (United States), Lexington, MA, United States., Udartseva O; Agenus (United States), Lexington, MA, United States., Vincent S; Agenus (United States), Lexington, MA, United States., Joshi B; Agenus (United States), Lexington, MA, United States., Keith JG; Agenus (United States), Lexington, MA, United States., Manrique M; Agenus (United States), Lexington, MA, United States., Marques M; Agenus (United States), Lexington, MA, United States., Tanne A; Agenus (United States), Lexington, MA, United States., Levey DL; Agenus (United States), Lexington, MA, United States., Han H; Translational Genomics Research Institute, Phoenix, AZ, United States., Ng S; TGEN, Phoenix, Arizona, United States., Ridpath J; Agenus (United States), Lexington, MA, United States., Huber O; Agenus (United States), Lexington, MA, United States., Morin B; Agenus Inc., Lexington, MA, United States., Galand C; Agenus (United States), Lexington, MA, United States., Bourdelais S; Agenus (United States), Lexington, MA, United States., Gombos RB; Agenus Inc., Lexington, MA, United States., Ward R; Agenus Inc, Lexington, MA, United States., Qin Y; Agenus (United States), Lexington, MA, United States., Waight JD; GlaxoSmithKline (United States), Collegeville, PA, United States., Costa MR; Agenus (United States), Lexington, MA, United States., Sebastian-Yague A; Agenus (United States), Cambridge, United Kingdom., Rudqvist NP; Agenus (United States), Lexington, MA, United States., Pupecka-Swider M; Agenus (United States), Cambridge, United Kingdom., Venkatraman V; Agenus (United States), Cambridge, United Kingdom., Slee A; Agenus (United States), Lexington, MA, United States., Patel JM; Agenus (United States), Lexington, MA, United States., Grossman JE; Agenus Inc., Lexington, MA, United States., Wilson NS; Agenus Inc., Lexington, MA, United States., Von Hoff DD; Translational Genomics Research Institute, Phoenix, United States., Stebbing J; Anglia Ruskin University, Cambridge, United Kingdom., Curiel TJ; Dartmouth Health and The Geisel Medical School at Dartmouth, Lebanon, NO, United States., Buell JS; Agenus Inc., Lexington, MA, United States., O'Day SJ; Agenus Inc., Lexington, MA, United States., Stein RB; Agenus (United States), Lexington, MA, United States.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.

Cost-effectiveness of primary and secondary prevention.

Autor: Cox S, Keith JG, Otten GL, Raymond FB 3rd

Publikováno v: Health & social work [Health Soc Work] 1980 May; Vol. 5 (2), pp. 56-60.

Hospital social work audit focuses on discharge planning.

Autor: Keith JG

Publikováno v: Hospitals [Hospitals] 1977 Dec 01; Vol. 51 (23), pp. 73-5.